These results suggested that evaluation of PR status in ER+ breast cancer might be used to help guide clinical management, as high levels of PR expression may identify a subset of ER+ patients most likely to benefit from hormonal therapy [7]. The gene discussed is PGR; the disease is breast carcinoma.